Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,106

Employees15,106

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,106

Employees15,106

REGN Key Statistics

Market cap

59.08B

Market cap59.08B

Price-Earnings ratio

13.93

Price-Earnings ratio13.93

Dividend yield

0.32%

Dividend yield0.32%

Average volume

1.10M

Average volume1.10M

High today

$551.56

High today$551.56

Low today

$535.84

Low today$535.84

Open price

$547.75

Open price$547.75

Volume

456.33K

Volume456.33K

52 Week high

$1,211.20

52 Week high$1,211.20

52 Week low

$476.49

52 Week low$476.49

REGN News

TipRanks 2d

Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Don’t Miss TipR...

TipRanks 2d

Eli Lilly and Regeneron: Exploring New Frontiers in Obesity Treatment

Eli Lilly And Company ((LLY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Tak...

TipRanks 3d

Regeneron and Sanofi’s Expanded Access Program for Dupilumab: A Potential Market Mover

Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study. Don’t Miss TipR...

Analyst ratings

70%

of 27 ratings

Buy

70.4%

Hold

25.9%

Sell

3.7%

More REGN News

Simply Wall St 5d

Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices

On June 30, 2025, was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the co...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.